Cargando…

Prognostic value of pretreatment (18)F-FDG PET-CT for nasopharyngeal carcinoma patients

BACKGROUND: Nasopharyngeal carcinoma (NPC) is a special subtype of head and neck cancer (HNC). At present, there are no highly specific prognostic markers to aid in tumor grading and guide patient treatment modalities for NPC. The prognostic value of pretreatment (18)F-fluorodeoxyglucose positron em...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yecai, Feng, Mei, He, Qiao, Yin, Jun, Xu, Peng, Jiang, Qinghua, Lang, Jinyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413252/
https://www.ncbi.nlm.nih.gov/pubmed/28445287
http://dx.doi.org/10.1097/MD.0000000000006721
_version_ 1783233151023185920
author Huang, Yecai
Feng, Mei
He, Qiao
Yin, Jun
Xu, Peng
Jiang, Qinghua
Lang, Jinyi
author_facet Huang, Yecai
Feng, Mei
He, Qiao
Yin, Jun
Xu, Peng
Jiang, Qinghua
Lang, Jinyi
author_sort Huang, Yecai
collection PubMed
description BACKGROUND: Nasopharyngeal carcinoma (NPC) is a special subtype of head and neck cancer (HNC). At present, there are no highly specific prognostic markers to aid in tumor grading and guide patient treatment modalities for NPC. The prognostic value of pretreatment (18)F-fluorodeoxyglucose positron emission tomography-computed tomography ((18)F-PET-CT) in NPC patients is controversial and no consensus exists as to its predictive capability. METHODS: To analyze the predictive efficacy of (18)F-PET-CT imaging in NPC patients, data from MEDLINE, EMBASE, the Cochrane library, CBM, CNKI, and VIP (inception to July 2016) were accessed. Results from prospective and retrospective observational studies that used (18)F-FDG PET to predict disease prognosis in NPC patients were used for analysis. Two authors independently assessed study quality and extracted data. Event-free survival (EFS) was considered the primary endpoint and overall survival rate (OS) was considered the secondary endpoint. RESULTS: Data from 14 studies and 1134 patients were included in our analysis. The hazard ratios (HRs) of maximum standardized uptake value of primary tumor (SUVmax-T), metabolic tumor volume of primary tumor (MTV-T), and total lesional glycolysis of primary tumor (TLG-T) for EFS were 1.31 (95% confidence interval [CI], 1.11–1.55, P = .001), 2.38 (95% CI 1.53–3.70, P < .001), and 1.65 (95% CI 0.76–3.59, P = .21), respectively. Among studies including TLG-T, those with a fixed SUV of 2.5 had an HR of 3.55 (95% CI, 1.42–8.84, P = .007). The HRs of SUVmax-T and MTV-T for OS were 2.19 (95% CI, 1.47–3.27, P < .001) and 2.69 (95% CI, 1.01–7.17, P = .05), respectively. Among studies including MTV-T, those with a fixed SUV of 2.5 had an HR of 4.07 (95% CI, 2.22–7.46, P < .001). Tests used for assessing predictive value of pretreatment SUVmax, MTV, and TLG of lymph nodes for EFS and OS showed that these parameters did not have significant predictive value (P>.05). CONCLUSION: Our results suggested that SUVmax, MTV, and TLG (with a fixed SUV of 2.5) of primary tumors before treatment initiation may be independent prognostic factors for NPC patients; however, SUVmax, MTV, and TLG of metastatic lymph nodes are not.
format Online
Article
Text
id pubmed-5413252
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-54132522017-05-05 Prognostic value of pretreatment (18)F-FDG PET-CT for nasopharyngeal carcinoma patients Huang, Yecai Feng, Mei He, Qiao Yin, Jun Xu, Peng Jiang, Qinghua Lang, Jinyi Medicine (Baltimore) 5700 BACKGROUND: Nasopharyngeal carcinoma (NPC) is a special subtype of head and neck cancer (HNC). At present, there are no highly specific prognostic markers to aid in tumor grading and guide patient treatment modalities for NPC. The prognostic value of pretreatment (18)F-fluorodeoxyglucose positron emission tomography-computed tomography ((18)F-PET-CT) in NPC patients is controversial and no consensus exists as to its predictive capability. METHODS: To analyze the predictive efficacy of (18)F-PET-CT imaging in NPC patients, data from MEDLINE, EMBASE, the Cochrane library, CBM, CNKI, and VIP (inception to July 2016) were accessed. Results from prospective and retrospective observational studies that used (18)F-FDG PET to predict disease prognosis in NPC patients were used for analysis. Two authors independently assessed study quality and extracted data. Event-free survival (EFS) was considered the primary endpoint and overall survival rate (OS) was considered the secondary endpoint. RESULTS: Data from 14 studies and 1134 patients were included in our analysis. The hazard ratios (HRs) of maximum standardized uptake value of primary tumor (SUVmax-T), metabolic tumor volume of primary tumor (MTV-T), and total lesional glycolysis of primary tumor (TLG-T) for EFS were 1.31 (95% confidence interval [CI], 1.11–1.55, P = .001), 2.38 (95% CI 1.53–3.70, P < .001), and 1.65 (95% CI 0.76–3.59, P = .21), respectively. Among studies including TLG-T, those with a fixed SUV of 2.5 had an HR of 3.55 (95% CI, 1.42–8.84, P = .007). The HRs of SUVmax-T and MTV-T for OS were 2.19 (95% CI, 1.47–3.27, P < .001) and 2.69 (95% CI, 1.01–7.17, P = .05), respectively. Among studies including MTV-T, those with a fixed SUV of 2.5 had an HR of 4.07 (95% CI, 2.22–7.46, P < .001). Tests used for assessing predictive value of pretreatment SUVmax, MTV, and TLG of lymph nodes for EFS and OS showed that these parameters did not have significant predictive value (P>.05). CONCLUSION: Our results suggested that SUVmax, MTV, and TLG (with a fixed SUV of 2.5) of primary tumors before treatment initiation may be independent prognostic factors for NPC patients; however, SUVmax, MTV, and TLG of metastatic lymph nodes are not. Wolters Kluwer Health 2017-04-28 /pmc/articles/PMC5413252/ /pubmed/28445287 http://dx.doi.org/10.1097/MD.0000000000006721 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-nc-sa/4.0
spellingShingle 5700
Huang, Yecai
Feng, Mei
He, Qiao
Yin, Jun
Xu, Peng
Jiang, Qinghua
Lang, Jinyi
Prognostic value of pretreatment (18)F-FDG PET-CT for nasopharyngeal carcinoma patients
title Prognostic value of pretreatment (18)F-FDG PET-CT for nasopharyngeal carcinoma patients
title_full Prognostic value of pretreatment (18)F-FDG PET-CT for nasopharyngeal carcinoma patients
title_fullStr Prognostic value of pretreatment (18)F-FDG PET-CT for nasopharyngeal carcinoma patients
title_full_unstemmed Prognostic value of pretreatment (18)F-FDG PET-CT for nasopharyngeal carcinoma patients
title_short Prognostic value of pretreatment (18)F-FDG PET-CT for nasopharyngeal carcinoma patients
title_sort prognostic value of pretreatment (18)f-fdg pet-ct for nasopharyngeal carcinoma patients
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413252/
https://www.ncbi.nlm.nih.gov/pubmed/28445287
http://dx.doi.org/10.1097/MD.0000000000006721
work_keys_str_mv AT huangyecai prognosticvalueofpretreatment18ffdgpetctfornasopharyngealcarcinomapatients
AT fengmei prognosticvalueofpretreatment18ffdgpetctfornasopharyngealcarcinomapatients
AT heqiao prognosticvalueofpretreatment18ffdgpetctfornasopharyngealcarcinomapatients
AT yinjun prognosticvalueofpretreatment18ffdgpetctfornasopharyngealcarcinomapatients
AT xupeng prognosticvalueofpretreatment18ffdgpetctfornasopharyngealcarcinomapatients
AT jiangqinghua prognosticvalueofpretreatment18ffdgpetctfornasopharyngealcarcinomapatients
AT langjinyi prognosticvalueofpretreatment18ffdgpetctfornasopharyngealcarcinomapatients